In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

After underperforming throughout 2024, shares of CVS Health (NYSE: CVS) are surging. CVS Health stock is way up but still ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

With retail space in scarce supply, it has not been difficult to entice new tenants to small spaces like Medical Arts ...

Bringing greater rigor and focus to food is medicine programs — which use food to prevent, manage or treat certain medical conditions — has been gaining momentum.

Donald Trump hosted meals with dozens of the corporate leaders during the presidential transition, in a lucrative venture.

Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

Neighborhood pharmacies are rapidly shuttering .Not long ago, Walgreens, one of the nation's biggest pharmacy chains, ...

Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...

Optum Rx, a subsidiary of UnitedHealth Group, on Friday filed a motion to dismiss the lawsuit brought by the family of Cole ...

This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. For many Americans, prescription medications are a regular part of their daily lives. While CivicScience ...